Hospitals using the MaxPlus™ Needle-free Connector had lower unadjusted CLABSI rates, as well as lower standardized infection ratios, compared to hospitals not using the MaxPlus™ Needle-free Connector.*
- Overview
- Specifications
- eIFUs and Resources
- FAQ
- Product Notifications
true
FEATURE AND BENEFIT CARDS NOT AVAILABLE
FEATURE AND BENEFIT CARDS NOT AVAILABLE
GTIN - each
10885403223228
1
GTIN - Case
50885403223226
100
GTIN - Multi case
20885403223225
2400
Natural Latex
No
Registered with Health Canada
Yes
Country of Manufacture
Mexico
CE Marking
No
Case Dimensions
6.25in x 6.25in x 5.5in 1.1lb
Quantity
100
Unit of Measure
Per case
Weight
1.1 lbs
Approximate Length
0 cm
Approximate Priming Volume
0.28 mL
Manifold
None
Number of Backcheck Valves
0
Number of Connectors
1
Number of Fuses
0
Pressure Rated
Yes
Sterility
Content sterile
Stock
None
Color of Tubing
None
T-Connector Type
None
Number of Y-Sites
0
Y-Site Port Type
None
Type of Connector
MaxPlus™ clear
Filter
None
GTIN
| GTIN - each | 10885403223228 | 1 |
| GTIN - Case | 50885403223226 | 100 |
| GTIN - Multi case | 20885403223225 | 2400 |
FDA, Premarket Approval, and Regulatory
| Natural Latex | No |
| Registered with Health Canada | Yes |
Manufacturing
| Country of Manufacture | Mexico |
| CE Marking | No |
Packaging
| Case Dimensions | 6.25in x 6.25in x 5.5in 1.1lb |
| Quantity | 100 |
| Unit of Measure | Per case |
Product Basic Specification
| Weight | 1.1 lbs |
| Approximate Length | 0 cm |
| Approximate Priming Volume | 0.28 mL |
| Manifold | None |
| Number of Backcheck Valves | 0 |
| Number of Connectors | 1 |
| Number of Fuses | 0 |
| Pressure Rated | Yes |
| Sterility | Content sterile |
| Stock | None |
| Color of Tubing | None |
| T-Connector Type | None |
| Number of Y-Sites | 0 |
| Y-Site Port Type | None |
| Type of Connector | MaxPlus™ clear |
| Filter | None |
false
Things to Consider
If you are a patient or end user, you can contact us yourself, or you may have your caregiver or your physician do that for you. To help us process your
information quickly and effectively, please contact our customer complaints
team.
To better facilitate our investigation, please include the following information in your reporting:
- Product Name and/or Catalog Number
- Lot Number or Serial Number
- Any injuries and/or Harm?
- What is the issue you experienced?
- Is the actual sample or sample representative available? (If possible, please send affected sample)
- Contact name and phone number
- Tabak YP, Jarvis WR, Sun X, Crosby CT, Johannes RS. Meta-analysis on central line-associated bloodstream infections associated with a needleless intravenous connector with a new engineering design. Am J Infect Control. 2014;42(12):1278–1284. doi: 10.1016/j.ajic.2014.08.018.
- Williams A. Catheter occlusion in home infusion: the influence of needleless connector design on central catheter occlusion. J Infus Nurs. 2018;41(1):52–57. doi: 10.1097/NAN.0000000000000259.
- Tabak YP, Johannes RS, Sun X, Crosby CT, Jarvis WR. Innovative use of existing public and private data sources for postmarketing surveillance of central line-associated bloodstream infections associated with intravenous needleless connectors. J Infus Nurs. 2016;39(5):328–335. doi: 10.1097/NAN.0000000000000185.
- Costello JM, Morrow DF, Graham DA, Potter-Bynoe G, Sandora TJ, Laussen PC. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics. 2008;121(5):915–923. doi: 10.1542/peds.2007-1577.
- Wallace MC, Macy DL. Reduction of central line-associated bloodstream infection rates in patients in the adult intensive care unit. J Infus Nurs. 2016;39(1):47–55. doi: 10.1097/NAN.0000000000000151.
- Sandora TJ, Graham DA, Conway M, Dodson B, Potter-Bynoe G, Margossian SP. Impact of needleless connector change frequency on central line-associated bloodstream infection rate. Am J Infect Control. 2014;42(5):485–489. doi: 10.1016/j.ajic.2014.01.022.
- Royer T. Implementing a better bundle to achieve and sustain a zero central line-associated bloodstream infection rate. J Infus Nurs. 2010;33(6):398–406. doi: 10.1097/NAN.0b013e3181f8586b.
- Casey AL, Karpanen TJ, Nightingale P, Chaganti S, Elliott TSJ. Microbiologic contamination of a positive- and a neutral-displacement needleless intravenous access device in clinical use. Am J Infect Control. 2016;44(12):1678–1680. doi: 10.1016/j.ajic.206.06.027.
- Clavier T, Ferguen M, Gouin P, et al. Impact of MaxZero™ needle-free connector on the incidence of central venous catheter-related infections in surgical intensive care unit. Aust Crit Care. 2019;32(2):107–111. doi: 10.1016/j.aucc.2018.03.003.
- Hankins R, Majorant OD, Rupp ME, et al. Microbial colonization of intravascular catheter connectors in hospitalized patients. Am J Infect Control. 2019;47(12):1489–1492. doi: 10.1016/j.ajic.2019.05.024.
- BD MaxPlus™ Needle-free Connector Directions for Use. 630-00658; 2015.
- Gorski LA, Hadaway L, Hagle ME, et al. Infusion Therapy Standards of Practice, 8th Edition. J Infus Nurs. 2021;44(1S,1):S1–S224. doi: 10.1097/NAN.0000000000000396.
- International Nosocomial Infection Control Consortium (INICC) Care bundles to prevent central and peripheral line-related bloodstream infections. INICC website. http://www.inicc.org/media/docs/2017-INICCBSIPreventionGuidelines.pdf. Published January 1, 2017. Accessed June 2, 2021.
- González López J, Arribi Vilela A, Fernández Del Palacio E, et al. Indwell times, complications and costs of open vs closed safety peripheral intravenous catheters: a randomized study. J Hosp Infect. 2014;86(2):117–126. doi: 10.1016/j.jhin.2013.10.008.
- Bausone-Gazda D, Lefaiver CA, Walters SA. A randomized controlled trial to compare the complications of 2 peripheral intravenous catheter-stabilization systems. J Infus Nurs. 2010;33(6):371–384.doi: 10.1097/NAN.0b013e3181f85be2.
- Hadaway L. Needleless connectors for IV catheters. Am J Nurs. 2012;112(11):32–44. doi: 10.1097/01.NAJ.0000422253.72836.c1.
- Curran E. Needleless connectors: the vascular access catheter’s microbial gatekeeper. J Infect Prev. 2016;17(5):234–240. doi: 10.1177/1757177416657164.
- Guenezan J, Marjanovic N, Drugeon B, et al. Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial. Lancet Infect Dis. 2021. doi: 10.1016/S1473-3099(20)30738-6.
BD-27572
true
true
